TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04030065
Drug: Omega 3 fatty acid
Normalized name: Omega 3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Omega-3 fatty acid oil will be supplemented in intravenous form from preoperative day 1, intra-operatively (anytime during surgery before reperfusion of graft) and from post operative day 1 to day 5 in the study group. The preparation used will be 100 ml injection which contains 10 gm of Omega 3 fatty acids.
Study: NCT00417404
Drug: Aquasol A
Normalized name: Aquasol A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM Aquasol A 10,000IU three times weekly
Study: NCT00417404
Drug: aquasol A
Normalized name: Aquasol A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10,000 IU three times weeks, by intramuscular injection
Study: NCT02349243
Drug: Entacapone
Normalized name: Entacapone
DrugBank: Entacapone (DB00494)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg entacapone, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
Study: NCT04243434
Drug: Vincristine Sulfate Liposome
Normalized name: vincristine sulfate liposome
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible patients will be randomized in a 1:1 ratio to one of 2 treatment cohorts (Cohorts A or B) to receive either the first cycle of treatment with the VSLI-RTU formulation or the Marqibo formulation and crossover to the other formulation for the second cycle.
Study: NCT00678041
Drug: Nitrofurantoin
Normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nitrofurantoin 100mg to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
Study: NCT03861403
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered by IV infusion
Study: NCT02861079
Drug: PGE2
Normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg PGE2 vaginal ovul (Propess,Ferring®) will place high into the posterior vaginal fornix.
Study: NCT01214720
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intervenous repeating dose
Study: NCT00165698
Drug: menatetranone
Normalized name: menatetrenone
DrugBank: Menatetrenone (DB12148)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg three times a day orally for 12 months
Study: NCT00165698
Drug: alfacalcidol
Normalized name: Alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 μg twice a day orally for 12 months
Study: NCT02595424
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02595424
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02704780
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 regimes of misoprostol 400 microgram and 800 microgram injections used for 2 groups of women
Study: NCT02595424
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01700036
Drug: Alpha-1-Antitrypsin (AAT)
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAT (Zemaira) will be administered at a dose of 60mg/kg (actual weight) on D1, 4, 8, 12, 16, 20, 24, and 28. A second course of treatment will not be given.
Study: NCT02595424
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT00433290
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: duloxetine 30 mg every day (QD), by mouth (PO) for 1 week, then duloxetine 60 mg QD, PO for 6 weeks, followed by duloxetine 60 mg QD, PO for 6 weeks for responders or duloxetine 120 mg QD, PO for 6 weeks for non-responders
Study: NCT04008186
Drug: Omaveloxolone
Normalized name: Omaveloxolone
DrugBank: Omaveloxolone (DB12513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg capsules
Study: NCT04008186
Drug: Midazolam oral solution
Normalized name: midazolam Oral Solution
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg/mL oral solution
Study: NCT04008186
Drug: Repaglinide 1 MG
Normalized name: repaglinide 1 MG
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg tablet
Study: NCT04008186
Drug: MetFORMIN 500 Mg Oral Tablet
Normalized name: metFORMIN 500 mg oral tablet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg tablet
Study: NCT04008186
Drug: Digoxin tablet
Normalized name: Digoxin Tablets
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25 mg tablet
Study: NCT04008186
Drug: Gemfibrozil Tablets
Normalized name: Gemfibrozil Tablets
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg tablet
Study: NCT04008186
Drug: Itraconazole capsule
Normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg capsule
Study: NCT04008186
Drug: Verapamil Pill
Normalized name: verapamil Pill
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120 mg tablet
Study: NCT00335075
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide orally for 5 consecutive days (Day 1 through Day 5) every 28 days, at a dose of 150 mg/m2/day for subjects previously treated with chemotherapy, or 200 mg/m2/day for subjects who have not received previous chemotherapy.
Study: NCT00335075
Drug: Semustine
Normalized name: Semustine
DrugBank: Semustine (DB13647)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semustine orally once every 28 days at a dose of 150 mg/m2/day.
Study: NCT02613013
Drug: Pilocarpine
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
Study: NCT01211080
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol 2mg/kg/day divided to three oral doses with or without concomitant physical therapy (cryotherapy, laser)
Study: NCT00729274
Drug: normal saline solution
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 4ml nebulizations with 30 minute interval
Study: NCT01916590
Drug: Bupivicaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with bupivacaine 0.25% solution (without epinephrine), and the infusion will be started at 6 ml/hr. gh the catheter.
Study: NCT00324649
Drug: Truvada
Normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Truvada once daily with continuation of the current NNRTI or PI at randomization.
Study: NCT00324649
Drug: Zidovudine/lamivudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of the zidovudine + lamivudine containing regimen plus the current NNRTI or PI at randomization.
Study: NCT00540293
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prescription of 10/20/40mg dose atorvastatin based on the personal risk factor that is defined in the NCEP ATP III guideline in a single patient group
Study: NCT00688376
Drug: Donepezil hydrochloride
Normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During the 12-week Double-Blind Phase, subjects will receive oral donepezil hydrochloride tablets starting at a dose of 3 mg once daily. Doses will be increased incrementally at successive 3-week intervals on the basis of weight and tolerability. The final daily dose will be 3, 5, or 10 mg depending on body weight.~During the Blinded Extension Phase, all subjects will receive active treatment (donepezil).
Study: NCT02564211
Drug: Ipragliflozin
Normalized name: ipragliflozin
DrugBank: Ipragliflozin (DB11698)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: one 50 mg tablet QD
Study: NCT02564211
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: one 50 mg tablet QD
Study: NCT03801889
Drug: SP-420
Normalized name: SP-420
DrugBank: SP-420 (DB16069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered by mouth
Study: NCT03282474
Drug: Sofosbuvir
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir 400 MG Oral Tablet \[Sovaldi\]
Study: NCT01327885
Drug: Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of dacarbazine at a dose of 850 mg/m\^2, or 1,000 mg/m\^2, or 1,200 mg/m\^2 selected by the Principal Investigator \[PI\] or designee according to the subject's clinical status as an IV infusion over 15-30 minutes on Day 1 of every cycle, where the duration of each cycle is 21 days.
Study: NCT00933309
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg tablets orally once a day
Study: NCT02770885
Drug: Dulaglutide
Normalized name: DULAGLUTIDE
DrugBank: Dulaglutide (DB09045)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment with dulaglutide for 3 weeks.
Study: NCT02277678
Drug: Opioid administration oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural administration single dose through epidural catheter
Study: NCT02277678
Drug: Opioid administration morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00149188
Drug: Lanreotide (Autogel formulation)
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00363753
Drug: aspirin versus clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00933309
Drug: Avandamet
Normalized name: Avandamet
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Beginning dose 2 mg rosiglitazone with 500 mg metformin hydrochloride (2mg/500 mg) tablets taken orally once a day
Study: NCT01059539
Drug: Cariprazine
Normalized name: Cariprazine
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cariprazine was supplied in capsules.
Study: NCT03893435
Drug: Sacubitril / Valsartan Oral Tablet [Entresto]
Normalized name: sacubitril / valsartan Oral Tablet [Entresto]
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sacubitril/Valsartan with the recommended starting dose: 24 mg/26 mg PO BID. After 2-4 weeks, the dose will be doubled to the target maintenance dose of 97 mg/103 mg PO BID (if tolerated) for 6 months.
Study: NCT04067336
Drug: Ziftomenib
Normalized name: Ziftomenib
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT02547935
Drug: Dapagliflozin 10 mg
Normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets administered orally once daily for 24 weeks.
Study: NCT02547935
Drug: Saxagliptin 2.5 mg
Normalized name: sAXagliptin 2.5 MG
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets administered orally once daily for 24 weeks.
Study: NCT02547935
Drug: Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets administered orally once daily for 24 weeks.
Study: NCT02571166
Drug: Valacyclovir
Normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg orally, once daily for 4 weeks
Study: NCT00847054
Drug: MORAb-004 (monoclonal antibody to TEM1)
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous administration
Study: NCT01415765
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CIV(continuous intravenous infusion) on days 1-4 of every 21 day cycle
Study: NCT01415765
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO (by mouth) twice daily on days 1-5 of every 21 day cycle
Study: NCT01415765
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CIV on days 1-4 of every 21 day cycle
Study: NCT00426192
Drug: i.v. mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00592839
Drug: SCE-B
Normalized name: Selegiline
DrugBank: Selegiline (DB01037)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.3 mg or 0.625 mg SCE-B tablets daily plus matching placebo
Study: NCT01415765
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV on day 1 of each 21 day cycle
Study: NCT01415765
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneously beginning Day 6 of each 21 day cycle
Study: NCT00004230
Drug: captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02858258
Drug: Ibrutinib (Induction)
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib: only in cycle 1,3,5 on Day 1-19
Study: NCT00390130
Drug: Pentacel (DPTaP+Hib)
Normalized name: Pentacel
DrugBank: Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (DB10076)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00390130
Drug: Prevnar (conjugated pneumococcal vaccine)
Normalized name: Prevnar 20
DrugBank: Streptococcus pneumoniae type 4 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10286)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00043758
Drug: Tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02666352
Drug: Uprifosbuvir
Normalized name: Uprifosbuvir
DrugBank: Uprifosbuvir (DB15206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of uprifosbuvir 450 mg (given as three 150-mg tablets) taken by mouth.
Study: NCT02666352
Drug: Ruzasvir
Normalized name: Ruzasvir
DrugBank: Ruzasvir (DB11713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of ruzasvir 60 mg (given as six 10-mg capsules) taken by mouth.
Study: NCT06458842
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02005887
Drug: triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days)
Study: NCT02005887
Drug: degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days)
Study: NCT02005887
Drug: letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole 2.5 mg orally every day for 6 cycles
Study: NCT02078336
Drug: Midazolam Mylan
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02078336
Drug: Lorazepam Mylan
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02078336
Drug: Valium + Akineton + Dehydrobenzperidol + Atropine sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02858258
Drug: Ibrutinib (Maintenance)
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib (Maintenance), daily 560 mg for 2 years;
Study: NCT00466219
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02387983
Drug: Posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole 300 mg solid oral tablet
Study: NCT00466219
Drug: Pegylated interferon alpha2a
Normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00308685
Drug: Albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol 90mcg
Study: NCT03598192
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine has been treated the both group
Study: NCT01660334
Drug: Voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole Intravenous Solution 200 mg:~Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.~Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:~administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.~Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.~However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.~In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.~Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily.
Study: NCT00093600
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00093600
Drug: daunorubicin hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00093600
Drug: midostaurin
Normalized name: Midostaurin
DrugBank: Midostaurin (DB06595)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01767285
Drug: Etonogestrel implant
Normalized name: Etonogestrel Implant
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.
Study: NCT01923623
Drug: Ropivacaine block
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02109510
Drug: nonintubated sedation anesthesia with dexmedetomidine IV, ketamine IV and intercostal nerve block with lidocaine infiltration
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02109510
Drug: intubated general anesthesia with propofol IV, rocuronium IV ,sevoflurane and N2O gas
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01948986
Drug: Ertugliflozin
Normalized name: Ertugliflozin
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single oral administration of 3 X 5 mg tablets.
Study: NCT00128414
Drug: Colchicine (for 6 months)
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: colchicine 1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 1 month in patients ≥70 kg, and halved doses for patients \<70 kg or intolerant to the highest dose.
Study: NCT00536263
Drug: pegylated interferon alpha-2b
Normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1.0 mcg/kg subcutaneously (S.C.) QW for 24 weeks
Study: NCT00536263
Drug: pegylated interferon alpha-2b
Normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1.5 mcg/kg S.C. QW for 24 weeks
Study: NCT00536263
Drug: pegylated interferon alpha-2b
Normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1.5 mcg/kg S.C. QW for 48 weeks
Study: NCT02548611
Drug: Prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: see arm description
Study: NCT02548611
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: see arm description
Study: NCT00436709
Drug: paclitaxel albumin-stabilized nanoparticle formulation
Normalized name: Albumin-stabilized nanoparticle (130 nm)
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02511184
Drug: Crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: To test 3 dose levels of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks
Study: NCT02838810
Drug: peginterferon alfa
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: peginterferon alfa-2b or peginterferon alfa-2a
Study: NCT00468650
Drug: sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, 50mg and 100mg , Medication will be taken orally with a glass of water approximately one hour (30 min to 4 hours) before sexual activity. Subjects are to take one dose in any calendar day.Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil 100 mg PRN for the following four weeks.
Study: NCT00643136
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin capsules 75 mg twice daily on Days 1-4, then 150 mg twice daily on Days 5-28
Study: NCT02365870
Drug: rotigotine transdermal patch
Normalized name: rotigotine Transdermal System
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive the dopamine agonist rotigotine in the form of a transdermal patch to be worn daily